HeartburnActive ingredient
Pantoprazole
Proton pump inhibitor1 FDA label read
Pantoprazole is sold as Protonix and has no over-the-counter version in the United States. Its label is narrower than the others here: erosive esophagitis associated with GERD, maintenance of that healing, and pathological hypersecretory conditions.
Highlights of the labels
- Protonix
- Erosive esophagitis in GERDcovers heartburn
- Supply
- Prescription only
- Generic
- 26 approved applications
- Boxed warning
- None in these labels
Brands and what each one is approved for
One active ingredient can hold several separate FDA approvals. They are different documents with different approved uses, and mixing them up is the most common mistake made about these medications.
| Brand | What its label approves | Supply | Label version |
|---|---|---|---|
| ProtonixWyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. | What its label approvesErosive esophagitis in GERDCovers heartburn | SupplyPrescription | Label version18 May 2026 |
How it works
Being prescription-only changes what the document has to say. There is no 14-day course and no instruction to stop after two weeks, because the decision to continue sits with a prescriber rather than with the person buying it.
Mechanism of action, Protonix label
Pantoprazole is a PPI that suppresses the final step in gastric acid production by covalently binding to the (H +, K +)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. The binding to the (H +, K +)-ATPase results in a duration of antisecretory effect that persists longer than 24 hours for all doses tested (20 mg to 120 mg).
What the FDA approved it for
The approved uses, as worded in the label.
- Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD)
- Maintenance of Healing of Erosive Esophagitis
- Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD) PROTONIX is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (EE).
Forms and strengths
The presentations and strengths listed in the label.
- Delayed-Release Tablets: 20 mg and 40 mg pantoprazole
- For Delayed-Release Oral Suspension: 40 mg pantoprazole
How the label says it is taken
What the label states about administration. It is not a dosing instruction for any individual.
Indication Dose Frequency Short-Term Treatment of Erosive Esophagitis Associated With GERD Adults 40 mg Once Daily for up to 8 wks Children (5 years and older) ≥ 15 kg to < 40 kg 20 mg Once Daily for up to 8 wks ≥ 40 kg 40 mg Maintenance of Healing of Erosive Esophagitis Adults 40 mg Once Daily Controlled studies did not extend beyond 12 months Pathological Hypersecretory Conditions Including...
Most common adverse reactions
The adverse reactions the label reports as most common.
Most common adverse reactions are: • For adult use (>2%): headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness, and arthralgia.
Warnings and precautions
The warnings and precautions section of the label.
- Gastric Malignancy: In adults, symptomatic response does not preclude presence of gastric malignancy. Consider additional follow-up and diagnostic testing.
- Acute Tubulointerstitial Nephritis: Discontinue treatment and evaluate patients.
- Clostridium difficile- Associated Diarrhea: PPI therapy may be associated with increased risk of Clostridium difficile- associated diarrhea.
- Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine.
- Severe Cutaneous Adverse Reactions: Discontinue at the first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation.
- Cutaneous and Systemic Lupus Erythematosus: Mostly cutaneous; new onset or exacerbation of existing disease; discontinue PROTONIX and refer to specialist for evaluation.
- Cyanocobalamin (Vitamin B-12) Deficiency: Daily long-term use (e.g., longer than 3 years) may lead to malabsorption or a deficiency of cyanocobalamin.
- Hypomagnesemia and Mineral Metabolism: Reported rarely with prolonged treatment with PPIs.
Contraindications
Situations in which the label states the medication must not be used.
- Patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles
- Patients receiving rilpivirine-containing products
Drug interactions
Interactions the label singles out.
There are other antiretroviral drugs which do not result in clinically relevant interactions with pantoprazole. Intervention: Rilpivirine-containing products: Concomitant use with PROTONIX is contraindicated. See prescribing information. Atazanavir: See prescribing information for atazanavir for dosing information. Nelfinavir: Avoid concomitant use with PROTONIX.
Pregnancy and breastfeeding
The opening of the pregnancy section of the label. The full section is longer and is in the source document.
Available data from published observational studies did not demonstrate an association of major malformations or other adverse pregnancy outcomes with pantoprazole. In animal reproduction studies, no evidence of adverse development outcomes was observed with pantoprazole.
Generic or brand
Generic pantoprazole sodium is approved and widely used.
The FDA label database lists 26 approved generic applications for this ingredient.
What affects the cost
Pantoprazole is generic. Where a pharmacy acquisition cost is published by CMS it is shown on this page; that figure is what pharmacies pay, not what a person pays.
What pharmacies pay for it
These are acquisition costs: what pharmacies in the United States pay on average to buy the medication, published weekly by the Centers for Medicare and Medicaid Services. They are not retail prices and not what a person pays at the counter, which depends on insurance, pharmacy and discount programs. They are useful as an objective floor and for seeing how far a brand sits above its generic.
| Measured | Brand | Generic |
|---|---|---|
| per tablet, capsule or pen | Brand$14.23 (range $14.08 to $14.31, 136 listings) | Generic$0.043 (range $0.035 to $4.60, 2689 listings) |
Median of 2825 listings. Effective dates 2025-05-21 to 2026-08-26, file dated 2026-08-26.
What the FDA has changed in these labels
The regulator reissues a label without notice: the old wording simply stops existing. These are the latest revisions on record for the documents this page is built from.
- 6 March 2023Protonixfrom the archive
Dosage and administration (3 added, 12 removed); Contraindications (1 added, 2 removed); Adverse reactions (reworded)
- 13 May 2022Protonixfrom the archive
Warnings and precautions (6 added, 1 removed); Adverse reactions (reworded)
- 11 December 2020Protonixfrom the archive
Contraindications (reworded); Warnings and precautions (4 added, 3 removed); Adverse reactions (reworded)
The full record for every label on this site - 6 earlier revisions for this ingredient are in the archive.
Compared with other medications
What the labels do not do is compare one medication against another. These pages put two of them side by side.
Common questions
- Can pantoprazole be bought without a prescription?
- Not in the United States. Omeprazole, esomeprazole and lansoprazole each have an approved over-the-counter product; pantoprazole does not.
- What is it approved for?
- Short-term treatment of erosive esophagitis associated with GERD, maintenance of healing of erosive esophagitis, and pathological hypersecretory conditions including Zollinger-Ellison syndrome. Its dosing section covers adults and children aged five and older.
Other medications under heartburn
Whether each one carries an FDA approval for this use is marked on its page and in this list.
Sources
Every fact above comes from one of these documents. The date is the effective date of the label version this page was built from.
FDA prescribing information for Protonix
Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.. Label version 48, effective 18 May 2026.
Each stripe is one section of the label, each division in a stripe one entry in that section.
Page last updated 29 August 2026
Compiled by the HealthyStudy editorial team from FDA source documents. No medical reviewer is credited on this page, because none reviewed it.